Adina R. D. Jensen
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Adina R. D. Jensen has a total of 30 co-authors. Here are the top co-authors by number of shared publications:
- Edward R. Horton
Biotech Research and Innovation Centre (BRIC), University of Copenhagen (UCPH), Copenhagen, Denmark
2 shared publications - Janine Terra Erler
Biotech Research and Innovation Centre (BRIC), University of Copenhagen (UCPH), Denmark
2 shared publications - Maria Rafaeva
Biotech Research and Innovation Centre (BRIC), University of Copenhagen (UCPH), Copenhagen, Denmark
2 shared publications - Raphael Reuten
Biotech Research and Innovation Centre, University of Copenhagen, Copenhagen, Denmark
2 shared publications - Sebastian Rune Nielsen
Department of Molecular and Clinical Cancer Medicine, University of Liverpool, Liverpool, United Kingdom
2 shared publications - Alejandro E. Mayorca-Guiliani
Biotech Research and Innovation Centre (BRIC), University of Copenhagen (UCPH), Copenhagen, Denmark.
1 shared publication
Latest Publications
- Open Access
- 3 November 2021
- Published by Wiley in Advanced Healthcare Materials
- Vol. 11 (1) , 2100684
Modeling Metastatic Colonization in a Decellularized Organ Scaffold‐Based Perfusion Bioreactor
Metastatic cancer spread is responsible for most cancer-related deaths. To colonize a new organ, invading cells adapt to, and remodel, the local extracellular matrix (ECM), a network of proteins and proteoglycans underpinning all tissues, and a critical regulator of homeostasis and disease. However, there is a major lack in tools to study cancer cell behavior within native three-dimensional ECM. Here, we present an in-house designed bioreactor, where mouse organ ECM scaffolds are perfused and populated with cells that are challenged to colonize it. Using a specialized bioreactor chamber, it is possible to monitor cell behavior microscopically (e.g., proliferation, migration) within the organ scaffold. Cancer cells in this system recapitulate cell signaling observed in vivo and remodel complex native ECM. Moreover, our bioreactors are compatible with co-culturing cell types of different genetic origin comprising the normal and tumor microenvironment. This degree of experimental flexibility in an organ-specific and three-dimensional context, opens new possibilities to study cell-cell and cell-ECM interplay, and to model diseases in a controllable organ-specific system ex vivo. This article is protected by copyright. All rights reserved
- 3 November 2021
- Published by Wiley in Advanced Healthcare Materials
- Vol. 11 (1) , 2100684
Open AccessModeling Metastatic Colonization in a Decellularized Organ Scaffold‐Based Perfusion Bioreactor
Metastatic cancer spread is responsible for most cancer-related deaths. To colonize a new organ, invading cells adapt to, and remodel, the local extracellular matrix (ECM), a network of proteins and proteoglycans underpinning all tissues, and a critical regulator of homeostasis and disease. However, there is a major lack in tools to study cancer cell behavior within native three-dimensional ECM. Here, we present an in-house designed bioreactor, where mouse organ ECM scaffolds are perfused and populated with cells that are challenged to colonize it. Using a specialized bioreactor chamber, it is possible to monitor cell behavior microscopically (e.g., proliferation, migration) within the organ scaffold. Cancer cells in this system recapitulate cell signaling observed in vivo and remodel complex native ECM. Moreover, our bioreactors are compatible with co-culturing cell types of different genetic origin comprising the normal and tumor microenvironment. This degree of experimental flexibility in an organ-specific and three-dimensional context, opens new possibilities to study cell-cell and cell-ECM interplay, and to model diseases in a controllable organ-specific system ex vivo. This article is protected by copyright. All rights reserved
- Open Access
- 7 June 2021
- Published by Springer Nature in Nature Communications
- Vol. 12 (1) , 1-15
Suppression of tumor-associated neutrophils by lorlatinib attenuates pancreatic cancer growth and improves treatment with immune checkpoint blockade
Pancreatic ductal adenocarcinoma (PDAC) patients have a 5-year survival rate of only 8% largely due to late diagnosis and insufficient therapeutic options. Neutrophils are among the most abundant immune cell type within the PDAC tumor microenvironment (TME), and are associated with a poor clinical prognosis. However, despite recent advances in understanding neutrophil biology in cancer, therapies targeting tumor-associated neutrophils are lacking. Here, we demonstrate, using pre-clinical mouse models of PDAC, that lorlatinib attenuates PDAC progression by suppressing neutrophil development and mobilization, and by modulating tumor-promoting neutrophil functions within the TME. When combined, lorlatinib also improves the response to anti-PD-1 blockade resulting in more activated CD8 + T cells in PDAC tumors. In summary, this study identifies an effect of lorlatinib in modulating tumor-associated neutrophils, and demonstrates the potential of lorlatinib to treat PDAC.
- 7 June 2021
- Published by Springer Nature in Nature Communications
- Vol. 12 (1) , 1-15
Open AccessSuppression of tumor-associated neutrophils by lorlatinib attenuates pancreatic cancer growth and improves treatment with immune checkpoint blockade
Pancreatic ductal adenocarcinoma (PDAC) patients have a 5-year survival rate of only 8% largely due to late diagnosis and insufficient therapeutic options. Neutrophils are among the most abundant immune cell type within the PDAC tumor microenvironment (TME), and are associated with a poor clinical prognosis. However, despite recent advances in understanding neutrophil biology in cancer, therapies targeting tumor-associated neutrophils are lacking. Here, we demonstrate, using pre-clinical mouse models of PDAC, that lorlatinib attenuates PDAC progression by suppressing neutrophil development and mobilization, and by modulating tumor-promoting neutrophil functions within the TME. When combined, lorlatinib also improves the response to anti-PD-1 blockade resulting in more activated CD8 + T cells in PDAC tumors. In summary, this study identifies an effect of lorlatinib in modulating tumor-associated neutrophils, and demonstrates the potential of lorlatinib to treat PDAC.